Top in endocrinology: Type 1 diabetes screening; cancer burden in type 2 diabetes
Click Here to Manage Email Alerts
With the availability of a medication that can delay the onset of type 1 diabetes, expanded screening for the disease has become more important, according to Richard Oram, MD, PhD.
However, many questions remain about how screening for type 1 diabetes should work as well as how to follow those people who are at high risk, especially because many may never develop the disease. It was the top story in endocrinology last week.
Another top story was about a study that found an increased cancer burden among older adults with type 2 diabetes.
Read these and more in endocrinology below:
Type 1 diabetes screening reaches ‘potentially pivotal moment’ with new treatment option
The benefits of type 1 diabetes screening have long been up for debate, but FDA approval of the first therapy to delay the disease’s onset may be changing the conversation. Read more.
Increased cancer burden in older adults with type 2 diabetes over past 20 years
Cancer burden among older adults with type 2 diabetes has increased in the past 2 decades while all-cause mortality rates at all ages have decreased, according to a 20-year population-based study published in Diabetologia. Read more.
Medicare beneficiaries could save about $500 per year with out-of-pocket insulin cap
Medicare Part B and Part D beneficiaries with diabetes who use insulin would have saved an average of $500 in 2020 if out-of-pocket insulin prices were capped at $35 that year, according to a report from HHS. Read more.
ED screening program identifies undiagnosed diabetes cases
An ED screening program identified patients with undiagnosed prediabetes and type 2 diabetes or undermanaged disease, particularly among racial and ethnic minorities and patients with low income, researchers reported in JAMA Network Open. Read more.
Phthalate exposure may increase metabolic syndrome risk for women with PCOS
Increased phthalate metabolite concentrations may contribute to obesity, glucose impairment and dislipidemia among women with polycystic ovary syndrome, according to study findings published in Clinica Chimica Acta. Read more.